Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Phaze Adds Lab, DEXA, and Taper Tools After User Feedback

Phaze, a popular app for people using GLP-1 drugs like Ozempic, just released an update (v3.1) after three months of listening to users. The update isn’t about flashy new marketing features. It’s a set of practical changes that people kept asking for. The developer collected complaints and suggestions from community forums and direct feedback, then built features to track lab results, body composition, and help with tapering doses. GLP-1 drugs are medications that mimic a natural gut hormone. In plain terms, they help you feel full and slow stomach emptying, which can lower appetite and help with blood sugar control. People use them for type 2 diabetes and, increasingly, for weight loss under a doctor’s care. Phaze is a tracker app meant to help users record doses, symptoms, and progress while using these drugs. The new lab-tracking features let users log and trend medical tests: A1C (a measure of average blood sugar over a few months), cholesterol and other lipids, kidney and liver tests, thyroid function, and vitamin D. You can now import DEXA scans (a precise body composition scan) and watch body fat percentage and lean mass change separately from total weight. There’s also a “taper coach” to help people record and plan gradual dose changes. This is not clinical research — it’s a product change based on user requests. The app doesn’t make medical claims about outcomes; it just gives better ways to store and visualize the data users already get from their doctors and scans. Why this matters to regular people: these additions make it easier to keep a fuller picture of health while on GLP-1 therapy. Weight alone can be misleading; tracking body fat and lean mass shows whether weight loss is mostly fat or muscle. Keeping A1C, liver, kidney, and thyroid numbers in one place helps people and their clinicians spot trends and side effects sooner. The taper coach could be useful for people working with a provider to reduce doses without losing track of changes in symptoms or labs. Caveats and risks: Phaze is a tracker, not a doctor. The app can store and display data, but it can’t diagnose or recommend treatment. Any changes to medication, including tapering, should be done under medical supervision. Imported scans and lab results are only as useful as their source; inconsistent testing or self-diagnosis can be misleading. Also, privacy and data security matter — check how the app handles your medical information. Finally, this update reflects user priorities, not new scientific evidence about GLP-1 drugs themselves. Bottom line: Phaze v3.1 adds lab tracking, DEXA import, and a tapering tool to help users and their clinicians get a clearer, more clinical view of health while using GLP-1 medications.

Source: r/Semaglutide

Read full story

Back to Riding the pepTIDE